An open-label pilot clinical trial of MAGE-A3 and MAGE-C1 mRNA electroporated autologous dendritic cell vaccination in combination with lenalidomide maintenance therapy for multiple myeloma after first-line autologous stem cell transplantation.
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Lenalidomide (Primary) ; TriMix DC (Primary) ; TriMix DC (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MYVAC2
- 17 Sep 2024 Status changed from recruiting to completed.
- 31 Jul 2017 New trial record